Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer

Lisa C. Moody, Xianfeng Wen, Teckshell McKnight, Celia Chao

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Multifocal and multicentric breast cancers have been regarded as relative contraindications for sentinel lymph node (SLN) biopsy, because initial validation studies noted an association with greater false-negative rates. The purpose of this study is to perform a meta-analysis of the literature evaluating the feasibility and accuracy of SLN biopsy in multifocal and multicentric breast cancer. Methods: A PubMed search retrieved original articles published between 2000 and 2010 in which the authors evaluated the accuracy of SLN biopsy in multifocal and multicentric breast cancer. Sixteen original articles were included in our meta-analysis. Results: Nine-hundred thirty-two patients with multifocal and multicentric breast cancer underwent SLN biopsy followed by axillary lymph node dissection. The overall accuracy rate and false-negative rate are 96% and 7.7%, respectively. Of the 37 false-negative biopsies, 7 patients had an additional relative contraindication for SLN biopsy. If we exclude these patients with additional known relative contraindication to SLN biopsy, the accuracy and false-negative rates are 96.7% and 6.3%, respectively. Conclusion: When a multifocal or multicentric breast cancer has an additional relative contraindication to performing SLN biopsy, such as neoadjuvant chemotherapy or T > 5 cm, the false-negative rate increases.

Original languageEnglish
Pages (from-to)389-396
Number of pages8
JournalSurgery (United States)
Volume152
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Sentinel Lymph Node Biopsy
Breast Neoplasms
Meta-Analysis
Validation Studies
Lymph Node Excision
PubMed
Biopsy
Drug Therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer. / Moody, Lisa C.; Wen, Xianfeng; McKnight, Teckshell; Chao, Celia.

In: Surgery (United States), Vol. 152, No. 3, 09.2012, p. 389-396.

Research output: Contribution to journalArticle

Moody, Lisa C. ; Wen, Xianfeng ; McKnight, Teckshell ; Chao, Celia. / Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer. In: Surgery (United States). 2012 ; Vol. 152, No. 3. pp. 389-396.
@article{71bef4818d8a4d70b8b1386eab5de22d,
title = "Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer",
abstract = "Background: Multifocal and multicentric breast cancers have been regarded as relative contraindications for sentinel lymph node (SLN) biopsy, because initial validation studies noted an association with greater false-negative rates. The purpose of this study is to perform a meta-analysis of the literature evaluating the feasibility and accuracy of SLN biopsy in multifocal and multicentric breast cancer. Methods: A PubMed search retrieved original articles published between 2000 and 2010 in which the authors evaluated the accuracy of SLN biopsy in multifocal and multicentric breast cancer. Sixteen original articles were included in our meta-analysis. Results: Nine-hundred thirty-two patients with multifocal and multicentric breast cancer underwent SLN biopsy followed by axillary lymph node dissection. The overall accuracy rate and false-negative rate are 96{\%} and 7.7{\%}, respectively. Of the 37 false-negative biopsies, 7 patients had an additional relative contraindication for SLN biopsy. If we exclude these patients with additional known relative contraindication to SLN biopsy, the accuracy and false-negative rates are 96.7{\%} and 6.3{\%}, respectively. Conclusion: When a multifocal or multicentric breast cancer has an additional relative contraindication to performing SLN biopsy, such as neoadjuvant chemotherapy or T > 5 cm, the false-negative rate increases.",
author = "Moody, {Lisa C.} and Xianfeng Wen and Teckshell McKnight and Celia Chao",
year = "2012",
month = "9",
doi = "10.1016/j.surg.2012.06.017",
language = "English",
volume = "152",
pages = "389--396",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Indications for sentinel lymph node biopsy in multifocal and multicentric breast cancer

AU - Moody, Lisa C.

AU - Wen, Xianfeng

AU - McKnight, Teckshell

AU - Chao, Celia

PY - 2012/9

Y1 - 2012/9

N2 - Background: Multifocal and multicentric breast cancers have been regarded as relative contraindications for sentinel lymph node (SLN) biopsy, because initial validation studies noted an association with greater false-negative rates. The purpose of this study is to perform a meta-analysis of the literature evaluating the feasibility and accuracy of SLN biopsy in multifocal and multicentric breast cancer. Methods: A PubMed search retrieved original articles published between 2000 and 2010 in which the authors evaluated the accuracy of SLN biopsy in multifocal and multicentric breast cancer. Sixteen original articles were included in our meta-analysis. Results: Nine-hundred thirty-two patients with multifocal and multicentric breast cancer underwent SLN biopsy followed by axillary lymph node dissection. The overall accuracy rate and false-negative rate are 96% and 7.7%, respectively. Of the 37 false-negative biopsies, 7 patients had an additional relative contraindication for SLN biopsy. If we exclude these patients with additional known relative contraindication to SLN biopsy, the accuracy and false-negative rates are 96.7% and 6.3%, respectively. Conclusion: When a multifocal or multicentric breast cancer has an additional relative contraindication to performing SLN biopsy, such as neoadjuvant chemotherapy or T > 5 cm, the false-negative rate increases.

AB - Background: Multifocal and multicentric breast cancers have been regarded as relative contraindications for sentinel lymph node (SLN) biopsy, because initial validation studies noted an association with greater false-negative rates. The purpose of this study is to perform a meta-analysis of the literature evaluating the feasibility and accuracy of SLN biopsy in multifocal and multicentric breast cancer. Methods: A PubMed search retrieved original articles published between 2000 and 2010 in which the authors evaluated the accuracy of SLN biopsy in multifocal and multicentric breast cancer. Sixteen original articles were included in our meta-analysis. Results: Nine-hundred thirty-two patients with multifocal and multicentric breast cancer underwent SLN biopsy followed by axillary lymph node dissection. The overall accuracy rate and false-negative rate are 96% and 7.7%, respectively. Of the 37 false-negative biopsies, 7 patients had an additional relative contraindication for SLN biopsy. If we exclude these patients with additional known relative contraindication to SLN biopsy, the accuracy and false-negative rates are 96.7% and 6.3%, respectively. Conclusion: When a multifocal or multicentric breast cancer has an additional relative contraindication to performing SLN biopsy, such as neoadjuvant chemotherapy or T > 5 cm, the false-negative rate increases.

UR - http://www.scopus.com/inward/record.url?scp=84865719695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865719695&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2012.06.017

DO - 10.1016/j.surg.2012.06.017

M3 - Article

C2 - 22938899

AN - SCOPUS:84865719695

VL - 152

SP - 389

EP - 396

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 3

ER -